Breakthrough Therapy Designation: Oncology Lessons, New Webinar Hosted by Xtalks - Tucson News Now

Breakthrough Therapy Designation: Oncology Lessons, New Webinar Hosted by Xtalks

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

With the introduction of a Breakthrough Therapy Designation (BTD), oncology therapies have become a target of related discussion and focus. To gain insights on this topic, join the live webinar broadcast taking place on Wednesday, July 16, 2014 at 11am EDT / 4pm BST (UK GMT +1).

Toronto, Canada (PRWEB) June 24, 2014

Much conversation and excitement have been generated since the introduction of a Breakthrough Therapy Designation (BTD) and oncology therapies have become an area of focus for this designation. With many questions surrounding the topic, this webinar will first provide an introduction to the criteria and process for obtaining FDAs BTD, including a working understanding of the use of the BTD in cancer therapies. Next, the role of timely and robust health economic and outcomes research (HEOR) data will be examined, reflecting how evidence can be generated to support a product with BTD.

Join speakers Jay Jackson, Vice President of GHEOR, and Kasia Puto, Associate Director at Xcenda, for an informative session using a case-study approach to demonstrate how quickly evolving data can affect timelines and impact HEOR initiatives in these scenarios.

Key take aways include:

  •     Knowledge of the key components of FDAs BTD
  •     Familiarity with the qualifying criteria for expedited programs
  •     Ability to discriminate between different pathways to FDA expedited drug development
  •     Awareness of products (oncology and non-oncology) that have been granted BTD status
  •     Recognition of HEOR opportunities and challenges specific to preparing and supporting a value story for a BTD product
  •     Expertise to apply these learnings to the development and commercialization of future BTD products

For more information or to register for this webinar, visit: Breakthrough Therapy Designation: Oncology Lessons.

About Xcenda
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. As part of AmerisourceBergen Corporation, a leading global healthcare solutions company, Xcenda supports global pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, Xcenda helps manufacturers identify, demonstrate, and deliver their brands value proposition to key healthcare stakeholders. For more information visit http://www.xcenda.com/.

About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx.

Contact:
Michelle Tran
Tel: +1 (416) 977-6555 ext 352
Email: mtran(at)xtalks(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/06/prweb11966744.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow